While early clinical trials hinted at TRAIL potential as a novel, tumor-specific therapy, this enthusiasm was impeded by the increasingly clear inability of TRAIL single therapy to reliably induce therapeutic response [17]. This evidence concerns the gene TNFSF10 and neoplasm.